A drugmaker that’s taking an unconventional approach to cancer drugs just got a $1.5 billion endorsement
|11/14/2017||Posted by BusinessMediaguide.Com under General World News||
- Bayer signed a partnership with cancer drugmaker Loxo Oncology in a deal that could be worth up to $1.5 billion.
- Loxo is developing treatments that act on cancerous genetic mutations, so that the type of cancer someone has wouldn’t matter so much as the genetic information gleaned from sequencing the tumor’s DNA.
- The company is planning to file for FDA approval by the end of 2017 or early 2018.
A company that’s building drugs that act on cancerous genetic mutations rather than the type of cancer a person has just got a $1.5 billion endorsement from pharmaceutical giant Bayer.
As part of read more >>>